Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVenture Life Regulatory News (VLG)

Share Price Information for Venture Life (VLG)

Share Price is delayed by 15 minutes
Get Live Data
65.50    -0.50 (-0.76%)
Bid:
65.00
Ask:
66.00
Spread: 1.00 (1.538%)
Market Cap: £79.80m
VLG Live PriceLast checked at - London Stock Exchange

Intraday Venture Life Share Chart

UltraDEX update

30 Oct 2017 07:00

RNS Number : 8997U
Venture Life Group PLC
30 October 2017
 

30 October 2017

Venture Life Group plc

("Venture Life" or "the Group")

 

UltraDEX update

 

Venture Life Group plc (AIM: VLG), the international consumer self-care group focused on developing, manufacturing and commercialising products for the ageing population, announces it has reached an agreement for its first launch of the UltraDEX brand into the convenience store channel.

 

Following a successful trial at one of their sites, the UK's leading provider of motorway service stations, Moto Hospitality Ltd., will launch UltraDEX mouth spray 9ml into WH Smith stores across its 61 service station outlets, effective from 16 November 2017. The convenience store channel has not yet been exploited by UltraDEX and offers a significant opportunity to access new customers. Distribution will be managed by Albert Harrison & Co. Ltd., which specialises in delivered wholesale of health & beauty, confectionary and stationery products. This agreement paves the way for future development of this important retail channel.

 

Following new long term partnering agreements announced previously this year, preparations for the new territories are on track in France, Italy and the Nordics, where UltraDEX is expected to be launched in Q1 2018.

 

Data from recent marketing activities has shown UltraDEX continues to perform well against its competitors in the UK, and the brand now has its highest ever level of listings countrywide.

 

Jerry Randall, CEO of Venture Life commented: "Achieving this first step onto the extensive convenience store channel has been a significant win for UltraDEX. Moto is the leading provider of convenience stores on the UK motorway network and enjoys meaningful footfall. I am delighted with the continued commercial development of the UltraDEX brand both in the UK and internationally, with the brand preparing to launch in a number of new European markets in Q1 2018, including France and Italy."

 

 

For further information please contact:

 

Venture Life Group PLC

+44 (0) 1344 742870

Jerry Randall, Chief Executive Officer

Adrian Crockett, Chief Financial Officer

Northland Capital Partners Limited (Nominated Adviser and Joint Broker)

+44 (0) 20 3861 6625

Matthew Johnson / Edward Hutton (Corporate Finance)

Bob Pountney / John Howes (Corporate Broking) 

Turner Pope Investments (TPI) Ltd (Joint Broker)

+44 (0) 20 3621 4120

James Pope / Ben Turner

Walbrook PR

venturelife@walbrookpr.com or + 44 (0) 20 7933 8780

Anna Dunphy / Paul McManus

+44 (0) 7876 741 001 / +44 (0) 7980 541 893

 

 

About Venture Life (www.venture-life.com)

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the ageing population. The Group's product portfolio includes some key products such as the UltraDEX oral care products range, food supplements for lowering cholesterol and maintaining brain function, medical devices for women's intimate healthcare and haemorrhoids and dermo-cosmetics for addressing the signs of ageing.

 

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies supplied by the Group's international distribution partners.

Through its Development & Manufacturing business in Italy, Biokosmes, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
PRLFEEFAAFWSEIS
Date   Source Headline
4th Jun 20267:00 amRNSDirector/PDMR Shareholding
3rd Jun 20267:00 amRNSAcquisition of FemiClear and CUROXEN
1st May 20262:39 pmRNSHolding(s) in Company
1st Apr 20264:30 pmRNSTotal Voting Rights
31st Mar 20267:01 amRNSTransaction in Own Shares
31st Mar 20267:00 amRNSInterim Results
30th Mar 20267:00 amRNSTransaction in Own Shares
27th Mar 20267:00 amRNSTransaction in Own Shares
26th Mar 20269:33 amRNSInvestor Presentation via Investor Meet Company
26th Mar 20267:00 amRNSTransaction in Own Shares
25th Mar 20267:00 amRNSTransaction in Own Shares
24th Mar 20267:00 amRNSTransaction in Own Shares
23rd Mar 20267:00 amRNSTransaction in Own Shares
20th Mar 20267:00 amRNSTransaction in Own Shares
19th Mar 20267:00 amRNSTransaction in Own Shares
18th Mar 20267:00 amRNSTransaction in Own Shares
17th Mar 20267:00 amRNSTransaction in Own Shares
17th Mar 20267:00 amRNSTransaction in Own Shares
16th Mar 20267:00 amRNSTransaction in Own Shares
16th Mar 20267:00 amRNSTransaction in Own Shares
13th Mar 20267:00 amRNSTransaction in Own Shares
13th Mar 20267:00 amRNSTransaction in Own Shares
12th Mar 20262:11 pmRNSGrant of Options and Director Dealing
12th Mar 20267:00 amRNSTransaction in Own Shares
10th Mar 20267:00 amRNSTransaction in Own Shares
10th Mar 20267:00 amRNSTransaction in Own Shares
9th Mar 20267:00 amRNSTransaction in Own Shares
6th Mar 20267:00 amRNSTransaction in Own Shares
5th Mar 20267:00 amRNSTransaction in Own Shares
4th Mar 20267:00 amRNSTransaction in Own Shares
3rd Mar 20267:00 amRNSTransaction in Own Shares
2nd Mar 20264:31 pmRNSTotal Voting Rights
2nd Mar 20267:00 amRNSTransaction in Own Shares
27th Feb 20267:00 amRNSTransaction in Own Shares
26th Feb 20267:00 amRNSTransaction in Own Shares
25th Feb 20267:00 amRNSTransaction in Own Shares
24th Feb 20267:00 amRNSTransaction in Own Shares
20th Feb 20267:00 amRNSTransaction in Own Shares
18th Feb 20267:00 amRNSTransaction in Own Shares
17th Feb 20267:00 amRNSTransaction in Own Shares
16th Feb 20267:00 amRNSTransaction in Own Shares
13th Feb 20263:07 pmRNSHolding(s) in Company
13th Feb 20267:00 amRNSTransaction in Own Shares
12th Feb 20265:40 pmRNSPCA Dealing
12th Feb 20267:00 amRNSTransaction in Own Shares
6th Feb 20267:00 amRNSTransaction in Own Shares
5th Feb 20267:00 amRNSTransaction in Own Shares
4th Feb 20267:00 amRNSTransaction in Own Shares
3rd Feb 20267:00 amRNSTransaction in Own Shares
2nd Feb 20264:30 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.